SCHEMBL22650785

SCHEMBL22650785

CC(C)(C)OC(=O)N1CCN(c2ccc(Cl)nc2)C(=O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
ENPP2 Q13822 2/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
AKR1C3 P42330 1/20 0.41
ESR2 Q92731 1/20 0.41
NR1H2 P55055 2/20 0.40
RAB9A P51151 1/20 0.40
GPR119 Q8TDV5 2/20 0.40
NPBWR1 P48145 1/20 0.40
MCHR1 Q99705 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
HRH3 Q9Y5N1 1/20 0.39
USP2 O75604 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29462384 1.00 POLB (0.44) POLBENPP2MEN1KMT2AMAPT
SCHEMBL255485 0.87 MAPT (0.44) POLBENPP2MEN1KMT2AMAPT
SCHEMBL29491152 0.87 MAPT (0.44) POLBENPP2MEN1KMT2AMAPT
SCHEMBL14845641 0.87 MAPT (0.48) POLBENPP2MEN1KMT2AMAPT
SCHEMBL1584044 0.85 GPR119 (0.48) ENPP2MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL14899254 0.84 MEN1 (0.54) ENPP2MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL255156 0.83 MAPT (0.51) POLBENPP2MEN1KMT2AMAPT
SCHEMBL29491170 0.83 MAPT (0.51) POLBENPP2MEN1KMT2AMAPT
SCHEMBL23408691 0.82 POLB (0.42) POLBENPP2MEN1KMT2AMAPT
SCHEMBL29361285 0.82 MAPT (0.57) POLBMEN1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120040446-A CDK inhibitors 基因泰克公司 2025-05-27 CN disclosed
CN-110818641-B Pyridazine-3-formamide compound, preparation method and application thereof in medicine and pharmacology 北京诺诚健华医药科技有限公司 2022-10-14 CN disclosed
US-20220296595-A1 CDK INHIBITORS GENENTECH, INC. 2022-09-22 US disclosed
CN-114364675-A CDK inhibitors 上海齐鲁锐格医药研发有限公司 2022-04-15 CN disclosed
EP-3966213-A1 CDK INHIBITORS Qilu Regor Therapeutics Inc. (CN) 2022-03-16 EP disclosed
WO-2020224568-A1 CDK INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2020-11-12 WO disclosed
CN-110818641-A Pyridazine-3-formamide compound, preparation method and application thereof in medicine and pharmacology 北京诺诚健华医药科技有限公司 2020-02-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220296595-A1 CDK INHIBITORS CDKL1, CDK9, CDK6 POLB 289/4885ENPP2 4177/4885MEN1 1994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.